Role Definition
| Field | Value |
|---|---|
| Job Title | Interventional Cardiologist |
| Seniority Level | Mid-to-Senior (board-certified, 5+ years post-fellowship) |
| Primary Function | Performs catheter-based cardiac procedures — percutaneous coronary intervention (angioplasty, stenting), transcatheter aortic valve replacement (TAVR), structural heart interventions (MitraClip, ASD/PFO closure, left atrial appendage occlusion), and peripheral vascular interventions. Works in cardiac catheterisation labs, hybrid operating rooms, and structural heart suites. Manages acute coronary syndromes (STEMI/NSTEMI), interprets coronary angiograms and hemodynamic data in real time, and provides post-procedural follow-up. |
| What This Role Is NOT | Not a general/non-invasive cardiologist (office-based imaging interpretation and chronic disease management — scored 70.4 GREEN Stable). Not a cardiac electrophysiologist (arrhythmia ablation, pacemaker/ICD — different fellowship, different procedures). Not a cardiovascular surgeon (open-heart surgery, sternotomy — scored 70.4 GREEN Transforming). Not a cardiovascular technologist (operates equipment under physician direction — scored 45.8 YELLOW). |
| Typical Experience | 4 years medical school (MD/DO) + 3 years internal medicine residency + 3 years cardiology fellowship + 1-2 years interventional cardiology fellowship + ABIM board certification in cardiovascular disease and interventional cardiology + state medical licence + DEA registration. 14-17+ years of training before independent practice. |
Seniority note: Seniority does not materially change the zone. All board-certified interventional cardiologists perform the same irreducible procedural core — catheter navigation, stent deployment, valve implantation. Senior operators take more complex structural heart cases (TAVR in hostile anatomy, chronic total occlusions) and programme leadership — equally or more AI-resistant.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 3 | Core work is physically threading guidewires and catheters through coronary arteries, deploying balloon-expandable and self-expanding stents, implanting transcatheter valves, and managing peri-procedural complications — all under live fluoroscopic guidance in variable patient anatomy. Every case involves manual catheter manipulation requiring sub-millimetre precision. |
| Deep Interpersonal Connection | 2 | Acute MI patients require immediate trust and consent under duress. Post-procedural follow-up involves long-term management of chronic coronary disease. Shared decision-making for TAVR vs SAVR involves nuanced patient-specific discussions. Trust is essential but procedural skill drives the role. |
| Goal-Setting & Moral Judgment | 3 | Real-time life-or-death decisions during catheterisation — whether to stent a borderline lesion, when to abort a chronic total occlusion attempt, whether to call for emergent surgical backup when a vessel perforates. Personal liability for every procedural outcome. Determines treatment strategy (medical vs interventional) with irreversible consequences. |
| Protective Total | 8/9 | |
| AI Growth Correlation | 0 | AI adoption does not create or destroy demand. Demand driven by cardiovascular disease (leading cause of death globally), aging population, and acute workforce shortage. |
Quick screen result: Protective 8/9 = Strong Green Zone signal. Proceed to confirm with task analysis.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Catheter-based coronary procedures (PCI, angioplasty, stenting, CTO) | 35% | 1 | 0.35 | NOT INVOLVED | Threading guidewires through coronary arteries, crossing lesions, deploying stents, managing dissections and no-reflow in real time. CorPath GRX robotic-assisted PCI was retracted from market (2023) for next-gen platform; R-One and AVIAR remain physician-controlled. No autonomous coronary catheter navigation exists or is FDA-approved. |
| Structural heart interventions (TAVR, MitraClip, closure devices) | 15% | 1 | 0.15 | NOT INVOLVED | Deploying transcatheter valves in calcified aortic roots, clip repair of mitral leaflets, closure of septal defects — all require manual device manipulation in unique patient anatomy under multimodality imaging. Caranx Medical's autonomous TAVR robot is research-stage only (in-vitro/in-vivo feasibility). |
| Pre-procedural planning, imaging review, case selection | 10% | 3 | 0.30 | AUGMENTATION | AI tools augment CT angiography analysis, automated valve sizing (Dasi Simulations + Medtronic), and coronary lesion complexity scoring. Interventionalist integrates imaging with clinical context to select approach, access site, and device. TAVIPILOT (FDA-cleared July 2025) provides real-time TAVR guidance — augmentation, not replacement. |
| Intra-procedural imaging and hemodynamic monitoring | 10% | 2 | 0.20 | AUGMENTATION | AI-enhanced fluoroscopy dose optimisation, automated hemodynamic waveform analysis, intravascular ultrasound co-registration. The operator interprets imaging in procedural context and adjusts technique based on real-time findings. AI improves the image; the physician acts on it. |
| Complication management and emergency response | 10% | 1 | 0.10 | NOT INVOLVED | Coronary perforation, stent thrombosis, no-reflow, tamponade — require immediate manual intervention (covered stent deployment, pericardiocentesis, balloon inflation). Unpredictable, high-stakes, irreducible manual dexterity and crisis judgment. No AI involvement. |
| Patient consultation, consent, post-procedure follow-up | 10% | 1 | 0.10 | NOT INVOLVED | Obtaining informed consent for life-threatening procedures, explaining STEMI management under time pressure, long-term management of dual antiplatelet therapy, shared decision-making for TAVR in elderly patients. Trust and human connection IS the value. |
| Documentation and administrative | 10% | 4 | 0.40 | DISPLACEMENT | Procedural reports, cath lab documentation, billing — increasingly automated by AI-populated structured reporting, ambient documentation (Nuance DAX), and AIMS integration. Interventionalist reviews and signs. |
| Total | 100% | 1.60 |
Task Resistance Score: 6.00 - 1.60 = 4.40/5.0
Displacement/Augmentation split: 10% displacement, 20% augmentation, 70% not involved.
Reinstatement check (Acemoglu): AI creates new tasks — validating AI-generated valve sizing recommendations, interpreting AI-flagged coronary lesion complexity scores, overseeing AI-driven post-TAVR monitoring, and evaluating AI-assisted procedural planning outputs. Net effect is augmentation and expanded procedural reach.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 2 | Acute shortage. 2025 IC Match: 307 positions offered, only 244 applicants — 71 unfilled across 49 programmes. ACC projects cardiologist-to-patient ratio worsening from 1:1,087 (2025) to 1:1,700 (2035). Shrinking trainee pipeline due to radiation exposure concerns, lead burden, and demanding STEMI call. |
| Company Actions | 2 | No health system cutting interventional cardiology positions citing AI. Hospitals aggressively recruiting with signing bonuses and retention premiums. SCAI convened emergency town halls on workforce pipeline crisis. MedAxiom projects net loss of 547 cardiologists/year from retirements outpacing training. |
| Wage Trends | 2 | Median total compensation ~$690,000 (SalaryDr 2026). Range $600K-$950K for permanent positions (AllStar Healthcare). 30-50% premium over general cardiology ($470K). Salaries surging — driven by acute shortage economics and procedural volume demand. |
| AI Tool Maturity | 1 | TAVIPILOT Soft (FDA-cleared July 2025) provides AI-guided TAVR planning. CorPath GRX retracted from market (2023). R-One and AVIAR physician-controlled robotic PCI. Caranx autonomous TAVR robot in research stage only. All tools augment — no autonomous coronary catheter navigation exists. Anthropic observed exposure: 2.97-8.4% (SOC 29-1229/29-1216). |
| Expert Consensus | 2 | SCAI (2025): workforce pipeline crisis, not AI displacement. Frontiers in Robotics (2025): autonomous TAVR "preparations for clinical trials ongoing" — years from production. ScienceDirect (2025): AI enhances procedural efficiency, does not replace operator. PMC systematic review (2025): AI in IC is augmentation-focused. No credible expert predicts IC displacement. |
| Total | 9 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | MD/DO + internal medicine residency (3yr) + cardiology fellowship (3yr) + interventional cardiology fellowship (1-2yr) + ABIM dual board certification + state medical licence + DEA registration. 14-17 years of training. No regulatory pathway for AI as independent proceduralist. FDA has not approved any autonomous interventional cardiac system. |
| Physical Presence | 2 | Must be physically present in the catheterisation laboratory for every procedure. Threading catheters through coronary arteries, deploying stents, implanting valves, and managing complications are irreducible manual tasks. No telemedicine pathway for PCI or TAVR. Robotic-assisted systems remain physician-controlled at the console. |
| Union/Collective Bargaining | 0 | Physicians are not meaningfully unionised. Among the highest-compensated medical professionals. Not a barrier. |
| Liability/Accountability | 2 | Personal malpractice liability for every catheterisation. Coronary perforation, stent thrombosis, stroke during TAVR, vascular access complications — all create substantial legal exposure. No insurer or hospital would accept "the AI navigated the catheter" as a liability defence. |
| Cultural/Ethical | 2 | Patients fundamentally expect a human physician to physically thread a catheter into their coronary arteries and deploy a device inside their heart. The concept of an autonomous robot performing PCI or TAVR without physician hands is culturally and ethically unacceptable for the foreseeable future. |
| Total | 8/10 |
AI Growth Correlation Check
Confirmed 0 (Neutral). AI adoption does not create or destroy interventional cardiology demand. Demand is driven by cardiovascular disease burden (leading cause of death globally), aging population requiring more TAVR and PCI, and a worsening workforce shortage — 71 unfilled fellowship positions in the 2025 Match, shrinking trainee pipeline. Not Accelerated Green — no recursive AI dependency.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 4.40/5.0 |
| Evidence Modifier | 1.0 + (9 × 0.04) = 1.36 |
| Barrier Modifier | 1.0 + (8 × 0.02) = 1.16 |
| Growth Modifier | 1.0 + (0 × 0.05) = 1.00 |
Raw: 4.40 × 1.36 × 1.16 × 1.00 = 6.9414
JobZone Score: (6.9414 - 0.54) / 7.93 × 100 = 80.7/100
Zone: GREEN (Green ≥48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 20% |
| AI Growth Correlation | 0 |
| Sub-label | Green (Transforming) — ≥20% task time scores 3+ |
Assessor override: None — formula score accepted. Score of 80.7 places IC above parent Cardiologist (70.4) and near Interventional Radiologist (76.2). The 10.3-point gap over the parent reflects the heavily procedural caseload — 70% of task time has zero AI involvement vs 20% for the general cardiologist. Higher than IR (76.2) is justified by IC's higher task resistance (4.40 vs 4.10) — 50% of IC task time is score-1 catheter procedures vs IR's 40%.
Assessor Commentary
Score vs Reality Check
The 80.7 score and Green (Transforming) label are honest. IC sits 32.7 points above the Green/Yellow boundary. Only 10% of task time (documentation) faces displacement. 20% is augmented and 70% is entirely untouched by AI. The "Transforming" sub-label reflects the 20% of task time where AI tools are materially changing workflow — primarily pre-procedural planning (AI valve sizing, CT analysis) and documentation automation. Core procedural work — catheter navigation, stent deployment, valve implantation, complication management — has no AI substitute and will not change materially over the next decade. The score is not barrier-dependent: strip barriers entirely (set to 0/10) and AIJRI would be 69.9 — still firmly Green.
What the Numbers Don't Capture
- Supply shortage confound. The interventional cardiology shortage (71 unfilled fellowship positions, shrinking trainee pipeline, $690K+ compensation) inflates evidence. If the pipeline recovered, evidence would soften — but the role remains Green on task analysis and barriers alone.
- Robotic-assisted PCI is real but stalled. CorPath GRX was retracted from market in late 2023. Siemens is developing a next-generation platform. Caranx Medical's autonomous TAVR robot is in research-stage feasibility studies. The trajectory is toward physician-controlled robotic assistance (analogous to da Vinci in surgery), not operator replacement. Timeline to production autonomous catheter navigation: 15-20+ years, if ever.
- General vs interventional divergence within the parent. The parent Cardiologist assessment (70.4) blends non-invasive and interventional work. Interventional cardiologists spend significantly more time on irreducible physical procedures (70% not AI-involved vs 20% for general cardiology). The 10.3-point gap is real and reflects genuine divergence in AI exposure.
Who Should Worry (and Who Shouldn't)
No mid-to-senior interventional cardiologist should worry about AI displacement. The interventional cardiologist physically performing PCI, TAVR, and structural heart procedures in the cath lab is among the most AI-resistant physicians in medicine — rivalling interventional radiologists and surgeons. Most protected: complex PCI operators (chronic total occlusions, bifurcation stenting, calcified lesions) and structural heart interventionalists performing TAVR and MitraClip. These involve the highest procedural complexity and most unpredictable anatomy. Slightly more exposed long-term (but still firmly Green): ICs whose practice has shifted toward diagnostic catheterisation without significant intervention — the angiography-only component faces more augmentation pressure than the treatment component. The single biggest separator: whether you are physically in the cath lab deploying devices inside a patient's heart. If you are, you are among the most AI-resistant roles in the entire economy.
What This Means
The role in 2028: Interventional cardiologists will use AI-enhanced pre-procedural planning as standard workflow — automated valve sizing for TAVR (TAVIPILOT, Dasi Simulations), AI-assisted coronary lesion complexity scoring, and 3D coronary reconstruction. Documentation burden drops substantially with ambient AI. Robotic-assisted PCI platforms may re-enter the market (Siemens next-gen, Robocath R-One expansion) as precision-enhancing, radiation-reducing tools under physician control. Core procedural work — catheter navigation, stent deployment, valve implantation, complication management — remains entirely human.
Survival strategy:
- Embrace AI-assisted procedural planning tools now — faster case preparation, better device selection, improved outcomes
- Develop structural heart expertise (TAVR, MitraClip, LAAO) — the fastest-growing and most complex segment of interventional cardiology, with the longest runway against automation
- Master next-generation robotic-assisted platforms as they re-enter the market — the interventionalist who leads human-robot collaboration in the cath lab defines the future of the specialty
Timeline: 20+ years. Driven by irreducible manual catheter procedures (no autonomous coronary navigation exists), 14-17 year training pipeline, personal malpractice liability for every catheterisation, FDA physician oversight requirements for invasive cardiac devices, and fundamental cultural expectation of a human physician performing surgery inside your heart.
